BT-001 is a multifunctional oncolytic virus
encoding for an anti-CTLA4 antibody and GM-CSF
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse.
Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.
BioInvent and Transgene are together creating a novel armed oncolytic virus that will be able to infect and selectively replicate within the tumor, inducing cancer cell destruction, and to elicit a strong immune response that is further enhanced by the local expression of the immune checkpoint inhibitor and the cytokine. This novel oncolytic virus is expected to deliver better treatment outcomes with an improved safety profile as the patient is not exposed to the the anti-CTLA4 antibody at a systemic level.
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic virusesHélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation
- BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
Download the abstract here
- BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
Download the poster here